Bacil Pharma: Rights Issue of up to Rs 50 Cr, two independent directors resign

Multiple Ind Directors ResignedManagement Changes View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.4%Reaction day

₹38.36

prior close

₹38.01

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.4%-1.0% vs market

Pharmaceuticals peers, median of 167sector+0.4%+0.0% vs sector

On the reaction day the stock moved 1.0 pts less than Nifty Microcap 250 and in line with its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+1.3

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.4+1.4-1.0+0.4+0.0

Next day

-2.2+1.5-3.7+0.8-3.0

-2.2+0.5-2.7+0.5-2.7

-3.9+1.1-5.0+0.6-4.5

-3.8+0.7-4.5+0.5-4.3

-4.8-0.4-4.4-0.7-4.2

-14.3+0.5-14.8+0.3-14.6

15d

-43.0+0.1-43.1-1.8-41.3

-58.1+3.5-61.6-0.6-57.5

-51.6+5.8-57.4+2.4-54.0

-36.3+2.4-38.6-1.5-34.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Bacil Pharma's board approved a Rights Issue of equity shares up to Rs 50 Crores and an Authorised Share Capital hike of Rs 45 Crores (post-increase Rs 65 Crores). Two Independent Directors, Mr. Dinesh Chander Notiyal and Ms. Avani Savjibhai Godhaniya, resigned effective 9 July 2026 due to time constraints. Axis Bank, Purva Sharegistry, and Acuite Ratings were appointed as intermediaries for the issue.

Likely market impact

Shareholders face potential dilution from a Rs 50 Crore Rights Issue; board loses two independent directors with no replacements named yet.